Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label randomized pilot study of pegylated interferon lambda for COVID-19
MOH_2020-05-04_008883Phase 2Recruiting
- Sponsor
- ד"ר אוהד עציון
- Start
- Apr 2020
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of peginterferon lambda-1a in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by ד"ר אוהד עציון. Started Apr 2020; status: recruiting.
02
Drugs
peginterferon lambda-1a
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on MOH_2020-05-04_008883.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-05-04_008883.